First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
Abstract Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older....
Guardado en:
Autores principales: | Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo, Yuka Fujita, Satoshi Oizumi, Ryo Morita, Yasuyuki Ikezawa, Hisashi Tanaka, Nozomu Kimura, Takaaki Sasaki, Noriaki Sukoh, Taichi Takashina, Toshiyuki Harada, Hirotoshi Dosaka-Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/30fdf5599db64195b591b2c71f3f2250 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Osimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report
por: Junjie GU, et al.
Publicado: (2021) -
Metabolomic analysis of skeletal muscle before and after strenuous exercise to fatigue
por: Hajime Ohmura, et al.
Publicado: (2021) -
Brain Processes Involved in Motor Planning Are a Dominant Factor for Inducing Event-Related Desynchronization
por: Kosei Nakayashiki, et al.
Publicado: (2021) -
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
por: Hirokazu Taniguchi, et al.
Publicado: (2019) -
Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Chin‐Chou Wang, et al.
Publicado: (2021)